LEXINGTON, Mass., Oct. 14, 2020 /PRNewswire/ -- Curis, Inc.
(NASDAQ: CRIS), a biotechnology company focused on the development
of innovative therapeutics for the treatment of cancer, today
announced that a Trial in Progress abstract for CI-8993, a
first-in-class monoclonal anti-VISTA antibody, has been accepted
for poster presentation at the Society for Immunotherapy of
Cancer's (SITC) 35th Anniversary Annual Meeting, which
will be held virtually from November 9-14,
2020.
Details of the poster session are as follows:
- Title: Phase 1 Study of CI-8993 anti-VISTA antibody in
patients with advanced solid tumor malignancies
- Author: Melissa L.
Johnson, MD, Sarah Cannon Research Institute
- Date & Time: Wednesday,
November 11th, 2020 – Saturday, November 14th, 2020 from
9:00 am – 5:00
pm ET
- Abstract ID: 743
Additional meeting information can be found on the SITC website
at www.sitcancer.org. The poster presentation will also be
available under "Events and Presentations" in the Investors section
of the Company's website at www.curis.com
About Curis, Inc.
Curis is a biotechnology
company focused on the development of innovative therapeutics for
the treatment of cancer. In 2015, Curis entered into a
collaboration with Aurigene in the areas of immuno-oncology
and precision oncology. As part of this collaboration, Curis has
exclusive licenses to oral small molecule antagonists of immune
checkpoints including, the VISTA/PDL1 antagonist CA-170, and the
TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor,
CA-4948. CA-4948 is currently undergoing testing in a Phase 1 trial
in patients with non-Hodgkin lymphoma and in a Phase 1 trial in
patients with acute myeloid leukemia and myelodysplastic syndromes.
In addition, Curis is engaged in a collaboration with ImmuNext for
development of CI-8993, a monoclonal anti-VISTA antibody, which is
currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is
also party to a collaboration with Genentech, a member of the Roche
Group, under which Genentech and Roche are commercializing
Erivedge® for the treatment of advanced basal cell
carcinoma. For more information, visit Curis' website at
www.curis.com.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/curis-announces-abstract-for-ci-8993-accepted-for-presentation-at-the-society-for-immunotherapy-of-cancers-sitc-35th-anniversary-annual-meeting-301152649.html
SOURCE Curis, Inc.